Predicting clinical trial results based on announcements of interim analyses

Trials

Volumn 15, Issue 1, 2014, Pages

  Broglio, Kristine R ^a   Stivers, David N ^b   Berry, Donald A ^a,c  

^a BERRY CONSULTANTS   (United States)

^b Alere   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bevacizumab; Colon cancer; DSMB; Interim analyses; Operational bias; Predictive probabilities; Prior distribution

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANALYSIS; ARTICLE; CANCER RECURRENCE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COLON CANCER; CONFIDENTIALITY; DISEASE FREE SURVIVAL; EXPERIMENTAL THERAPY; HUMAN; INTERIM ANALYSIS; PREDICTION; PREDICTIVE VALUE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; STUDY DESIGN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIAS (EPIDEMIOLOGY); CLINICAL PROTOCOLS; COLONIC NEOPLASMS; COMPUTER SIMULATION; EARLY TERMINATION OF CLINICAL TRIALS; HUMANS; MEDICAL FUTILITY; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897954467     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-73     Document Type: Article

References (22)

1. Oncothyreon CEO: Investors had " unrealistic expectations" . http://blogs.marketwatch.com/thetell/2012/03/09/oncothyreon-ceo-investors-had-%e2%80%98unrealistic-expectations%e2%80%99/]. Accessed April 10, 2012.
2. Oncothyreon: possible pharma blockbuster. [http://seekingalpha.com/article/280439-oncothyreon-possible-pharma-blockbuster]. Accessed Feburary 1, 2014.
3. Kahneman D. Thinking, Fast and Slow 2011, Farrar, Straus and Giroux: New York, NY, 1.
4. Fisher LD, VanBelle G. Biostatistics : a Methodology for the Health Sciences 1993, New York, NY: Wiley.
5. Berry DA, Stangl D. Bayesian Biostatistics 1996, New York, NY: CRC Press, 1.
6. Berry DA. Multiplicities in cancer research: Ubiquitous and necessary evils. J Natl Cancer Inst 2012, 104:1125-1133. Berry DA.
7. Ioannidis JPA. Why most published research findings are false. PLoS Med 2005, 2:e124. 10.1371/journal.pmed.0020124, 1182327, 16060722.
8. Hay M, Thomas DW, Rosenthal J, Economides C, Craighead JL. Clinical Development Success Rates for Investigational Drugs. [http://www.pharmaciconference.com/files/Clinical_Development_Success_Rates_for_Investigational_Drugs.pdf]. Accessed March 11, 2014.
9. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29:11-16. 10.1200/JCO.2010.30.0855, 3055856, 20940184.
10. Gordon Lan KK, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
12. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544. 10.1200/JCO.2006.09.6305, 17442997.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
14. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006, 24:2059-2064. 10.1200/JCO.2005.04.7498, 16648506.
15. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204. 10.1200/JCO.2006.08.2974, 17470851.
16. Berger JO, Berry DA. Statistical analysis and the illusion of objectivity. Am Sci 1988, 76:159-165.
17. Roche's bid for Genentech far below asking price. TechZone360 2009, [http://www.techzone360.com/news/2009/02/10/3979331.htm] Accessed April 10, 2012.
18. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group. J Biopharm Stat 2006, 16:275-283. discussion 285-291, 293-298, 311-312, 10.1080/10543400600614742, 16724485.
19. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011, 9:199-207. 10.1038/nrclinonc.2011.165, 22064459.
20. Fleming TR. Standard versus adaptive monitoring procedures: a commentary. Stat Med 2006, 25:3305-3312. 10.1002/sim.2641, 16850447.
21. Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Inf J 2006, 40:445-450.
22. U.S. Department of Health and Human Services Food and Drug Administration/Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (Draft) 2010, Silver Spring, MD: , Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm201790.pdf, U.S. Department of Health and Human Services Food and Drug Administration/Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research.